IV Ibogaine Safety: How Cardiac Monitoring Works During an Infusion

Definition

Definition: Cardiac monitoring during an IV ibogaine infusion means continuous, physician-supervised ECG observation (telemetry) from before the psychoactive dose starts until well after it ends, with trained staff, emergency equipment and written stop rules in the room. Ibogaine Infusion is a clinic dedicated exclusively to IV ibogaine therapy, so monitoring is not an add-on here; it is the reason the route exists. Evidence gap: Most published ibogaine research used oral ibogaine HCl, and there are no controlled trials of psychoactive IV ibogaine. Ibogaine can prolong the QTc interval. It is a U.S. Schedule I substance and is not approved for any indication.

Short answer

Ibogaine can delay the heart's electrical recovery (QTc prolongation), which can trigger dangerous arrhythmias such as torsades de pointes. During an IV infusion, a baseline 12-lead ECG, continuous telemetry, electrolyte checks and a physician watching the trace allow the dose to be given in small increments and slowed or stopped. That control does not remove cardiac risk, and IV safety has not been tested in controlled trials.

Why the heart is the central safety question

The QT interval on an ECG reflects how long the heart's ventricles take to recover between beats. Corrected for heart rate, it is called QTc. When QTc stretches too far, the risk of torsades de pointes, a fast and unstable rhythm that can become fatal, rises.

Ibogaine's effect on cardiac potassium channels (hERG) is the mechanism most often discussed for this delay. It is not theoretical. In the Knuijver 2021 QTc study, an open-label observational study of oral ibogaine in 14 opioid-dependent patients, half reached a QTc above 500 ms during observation. Deaths linked to ibogaine have been reported in non-medical and medical-adjacent settings, with arrhythmia frequently discussed as the mechanism. See our review of ibogaine heart risks.

That is why cardiac screening decides who can be treated, and why monitoring is never negotiable once treatment begins.

Before the infusion: screening that sets the baseline

Monitoring works when the team knows what "normal" looks like for you. Screening themes on our safety and screening page include:

• A baseline 12-lead ECG with QTc read by a physician
• Electrolytes such as potassium and magnesium, and kidney and liver labs as indicated
• A full medication and supplement list, because many common drugs also prolong QTc (see ibogaine drug interactions)
• Personal or family history of sudden death, fainting, long QT or cardiomyopathy
• Substance-use timing, because withdrawal itself stresses the body
• A psychiatric risk assessment and observation plan

Some people are declined at this stage. That is the system working, not failing. Our contraindications guide explains common reasons.

During the infusion: what monitoring actually looks like

On this site, "IV ibogaine infusion" means the psychoactive dose itself is delivered intravenously, not oral ibogaine with a saline line. The IV vs oral comparison explains the difference in detail. In practical terms, a monitored infusion involves:

1. Continuous telemetry. The ECG trace runs for the whole session, not as spot checks.
2. Physician supervision. A physician, not a coordinator, owns go and no-go decisions and watches the QTc trend.
3. Small, titrated increments. The dose is delivered gradually, guided by the ECG and clinical response.
4. Stop rules written in advance. The team agrees beforehand what changes on the trace mean slowing, pausing or stopping.
5. Support IV, labeled separately. Fluids, magnesium, potassium or anti-nausea medicine may run through the line as support. Support IV is not the treatment. See support IV vs psychoactive IV.
6. Emergency readiness. Staff trained in advanced cardiac life support, a defibrillator, emergency medicines and a written transfer plan. See telemetry and ACLS standards.

Our waitlist cohorts are small because every infusion has one-to-one cardiac monitoring.

Why IV allows more control, and what it does not prove

Once an oral dose is swallowed, it cannot be taken back or reduced. Absorption also varies with the gut and with CYP2D6 metabolism, which differs from person to person (see CYP2D6 and ibogaine). An IV infusion can be slowed or stopped at any point while clinicians watch the ECG.

That is a real practical difference. It is not evidence that IV ibogaine is safer overall. No controlled trial has compared cardiac outcomes between IV and oral ibogaine. The landmark papers people cite, including Knuijver 2021 and the Stanford-affiliated MISTIC study (Cherian et al., *Nature Medicine*, 2024), used oral ibogaine, in MISTIC's case alongside IV magnesium as support. Anyone who tells you IV ibogaine is "proven safe" is overstating the evidence.

After the infusion: why monitoring continues

Cardiac risk does not end when the infusion stops. Ibogaine is metabolized in part to noribogaine, an active metabolite that remains in the body longer than the parent drug. Because of that, the heart rhythm is watched into recovery rather than switched off when dosing ends. Recovery observation usually includes:

• Ongoing telemetry and repeat ECG review
• Hydration and electrolyte management
• Precautions for ataxia (unsteadiness) and falls
• Psychiatric check-ins and clear criteria for escalating care

Ask any program how long telemetry continues after dosing, and get the answer in writing.

Questions to ask about cardiac monitoring

• Who reads my ECG, and what QTc findings would exclude me?
• Is telemetry continuous for the whole session and recovery, and for how long?
• Is a physician on site during the infusion?
• Are ACLS-trained staff, a defibrillator and emergency medicines in the room?
• What are the written stop rules for slowing or stopping the infusion?
• What is the hospital transfer plan if something goes wrong?

A program that cannot answer these clearly is not ready to give you a QTc-prolonging drug. More detail: the ibogaine ECG checklist and what to expect from an IV ibogaine session. For how the route is defined, see what IV ibogaine infusion is.

FAQ

Is IV ibogaine safer for the heart than oral ibogaine?

It has not been shown to be. IV delivery lets clinicians give the dose gradually and stop it while watching the ECG, but no controlled trial has compared cardiac safety between IV and oral ibogaine. Most published research used oral dosing.

What does cardiac monitoring during an ibogaine infusion involve?

A baseline 12-lead ECG, continuous telemetry throughout the infusion and recovery, electrolyte checks, physician supervision, written stop rules, and ACLS-trained staff with a defibrillator and emergency medicines on hand.

Why does monitoring continue after the infusion ends?

Ibogaine's active metabolite, noribogaine, stays in the body longer than ibogaine itself, so cardiac risk is not assumed to end with dosing. Observation and telemetry continue into recovery for that reason.

Can I be turned away because of my ECG?

Yes. A prolonged QTc, certain heart conditions, interacting medications or electrolyte problems can make treatment unsafe. Being declined after screening protects you.

Medical disclaimer

This is educational content, not medical or legal advice and not a promise of any outcome. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events, including torsades de pointes and death. Most published research used oral ibogaine, and there are no controlled trials of psychoactive IV ibogaine. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs at our Mexico and Gabon intake locations are not approved U.S. clinics.

Next step

Read safety and screening to see what the cardiac work-up covers, then apply confidentially to start physician screening.